Since the dysfunction of NRF2 has been reported to potentiate skin inflammation (28), activators of the AHR-NRF2 axis should be candidate therapeutic agents for inflammatory skin diseases such as AD and psoriasis (14). This evidence concerns the gene AHR and inflammatory skin disease.